AU2017358401B2 - Subtilase cytotoxin B subunit mutant - Google Patents

Subtilase cytotoxin B subunit mutant Download PDF

Info

Publication number
AU2017358401B2
AU2017358401B2 AU2017358401A AU2017358401A AU2017358401B2 AU 2017358401 B2 AU2017358401 B2 AU 2017358401B2 AU 2017358401 A AU2017358401 A AU 2017358401A AU 2017358401 A AU2017358401 A AU 2017358401A AU 2017358401 B2 AU2017358401 B2 AU 2017358401B2
Authority
AU
Australia
Prior art keywords
linked
variant
seq
isolated protein
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017358401A
Other languages
English (en)
Other versions
AU2017358401A1 (en
Inventor
Christopher Day
Michael Paul Jennings
Adrienne Webster Paton
James Cleland Paton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Adelaide University
Original Assignee
University of Adelaide
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016904572A external-priority patent/AU2016904572A0/en
Application filed by University of Adelaide, Griffith University filed Critical University of Adelaide
Publication of AU2017358401A1 publication Critical patent/AU2017358401A1/en
Application granted granted Critical
Publication of AU2017358401B2 publication Critical patent/AU2017358401B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
AU2017358401A 2016-11-09 2017-11-09 Subtilase cytotoxin B subunit mutant Active AU2017358401B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016904572A AU2016904572A0 (en) 2016-11-09 Subtilase cytotoxin b subunit mutant
AU2016904572 2016-11-09
PCT/AU2017/051230 WO2018085888A1 (en) 2016-11-09 2017-11-09 Subtilase cytotoxin b subunit mutant

Publications (2)

Publication Number Publication Date
AU2017358401A1 AU2017358401A1 (en) 2019-05-30
AU2017358401B2 true AU2017358401B2 (en) 2022-01-13

Family

ID=62109062

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017358401A Active AU2017358401B2 (en) 2016-11-09 2017-11-09 Subtilase cytotoxin B subunit mutant

Country Status (9)

Country Link
US (2) US11371033B2 (enExample)
EP (1) EP3538544B1 (enExample)
JP (1) JP7123921B2 (enExample)
KR (1) KR102703633B1 (enExample)
CN (1) CN110402251A (enExample)
AU (1) AU2017358401B2 (enExample)
CA (1) CA3044303A1 (enExample)
ES (1) ES2983352T3 (enExample)
WO (1) WO2018085888A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112760305B (zh) * 2021-01-25 2022-04-29 浙江工业大学 一种栖热腔菌磷酸酶突变体及其应用
CN117651868A (zh) * 2021-05-06 2024-03-05 伊诺维吉股份有限公司 与肿瘤源性胞外囊泡相关的方法
WO2022236383A1 (en) * 2021-05-14 2022-11-17 The University Of Adelaide Methods of analysing a sample

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136424A1 (en) * 2003-12-22 2005-06-23 Paton Adrienne W. Cytotoxin with a subtilase domain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP1386927B1 (en) 2002-08-02 2005-03-30 Institut Curie Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors
EP2667898A1 (en) 2011-01-26 2013-12-04 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136424A1 (en) * 2003-12-22 2005-06-23 Paton Adrienne W. Cytotoxin with a subtilase domain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATON A.W. et al. "A New Family of Potent AB5 Cytotoxins Produced by Shiga Toxigenic Escherichia coli" J. Exp. Med. (2004) 200(1): 35-46 *

Also Published As

Publication number Publication date
JP2020501521A (ja) 2020-01-23
EP3538544B1 (en) 2024-03-27
EP3538544A4 (en) 2020-04-15
ES2983352T3 (es) 2024-10-22
CA3044303A1 (en) 2018-05-17
KR20190084995A (ko) 2019-07-17
JP7123921B2 (ja) 2022-08-23
EP3538544A1 (en) 2019-09-18
US20190367895A1 (en) 2019-12-05
US11371033B2 (en) 2022-06-28
AU2017358401A1 (en) 2019-05-30
US20220372459A1 (en) 2022-11-24
WO2018085888A1 (en) 2018-05-17
KR102703633B1 (ko) 2024-09-05
CN110402251A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
JP7479435B2 (ja) 癌治療および判断ターゲットとしてのｌｙ７５
US20220372459A1 (en) Subtilase cytotoxin b subunit mutant
EP1560597A2 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
CN101878302A (zh) 绿脓杆菌的外膜蛋白质pa4710
Sakuda et al. Reactivity of anti-HNK-1 antibodies to branched O-mannose glycans associated with demyelination
ES2615256T3 (es) Objetivo terapéutico y de diagnóstico
Sandhu et al. Detection of Staphylococcus aureus cell walls by enzyme-linked immunoassay using antibodies prepared from a semi-synthetic peptidoglycan precursor
US20070218001A1 (en) Biotherapeutics, Diagnostics and Research Reagents
CA2399047C (en) Reagents and methods useful for detecting diseases of the breast
EP2009105A1 (en) Novel serotype Streptococcus mutans and utilization of the same
US20140341895A1 (en) PSEUDOMONAS AERUGINOSA OprM EPITOPES FOR USE IN DIAGNOSTICS AND THERAPEUTICS
Serna et al. Minimal epitope for Mannitou IgM on paucimannose-carrying glycoproteins
WO2024077287A2 (en) Methods for actively loading therapeutic molecules into modified extracellular vesicles for targeted delivery to cells
EP3293520B1 (en) A method for the production of an polypeptide
JP4819504B2 (ja) 新規血清型のストレプトコッカスミュータンスおよびその利用
KR20150131655A (ko) Aimp2-dx2-34s 단백질 및 이의 제조방법
CN100506988C (zh) 新型血清型变形链球菌及其利用
Matikainen et al. Monoclonal antibodies against human osteocalcin made by using recombinant GST-rhOC as an immunogen
Hu Role of terminal sialic acid of GABA transporter 1 in GABA uptake & purification and characterization of this transporter for structural analysis
WO2006113648A2 (en) Hn-33 compositions and methods

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)